New daily persistent headache: A systematic review and meta-analysis.

Autor: Cheema S; Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.; The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK., Mehta D; Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.; The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK., Ray JC; Department of Neurology, Alfred Health, Melbourne, Australia.; Department of Neuroscience, Monash University, Melbourne, Australia.; Department of Neurology, Austin Health, Melbourne, Australia., Hutton EJ; Department of Neurology, Alfred Health, Melbourne, Australia.; Department of Neuroscience, Monash University, Melbourne, Australia., Matharu MS; Headache and Facial Pain Group, University College London (UCL) Queen Square Institute of Neurology, London, UK.; The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Jazyk: angličtina
Zdroj: Cephalalgia : an international journal of headache [Cephalalgia] 2023 May; Vol. 43 (5), pp. 3331024231168089.
DOI: 10.1177/03331024231168089
Abstrakt: Objective: To perform a systematic review and meta-analysis of the epidemiology, precipitants, phenotype, comorbidities, pathophysiology, treatment, and prognosis of primary new daily persistent headache.
Methods: We searched PubMed/Medline, EMBASE, Cochrane, and clinicaltrials.gov until 31 December 2022. We included original research studies with any design with at least five participants with new daily persistent headache. We assessed risk of bias using National Institutes of Health Quality Assessment Tools. We used random-effects meta-analysis where suitable to calculate pooled estimates of proportions. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis compliant study is registered with PROSPERO (registration number CRD42022383561).
Results: Forty-six studies met inclusion criteria, predominantly case series, including 2155 patients. In 67% (95% CI 57-77) of cases new daily persistent headache has a chronic migraine phenotype, however new daily persistent headache has been found to be less likely than chronic migraine to be associated with a family history of headache, have fewer associated migrainous symptoms, be less vulnerable to medication overuse, and respond less well to injectable and neuromodulatory treatments.
Conclusions: New daily persistent headache is a well described, recognisable disorder, which requires further research into its pathophysiology and treatment. There is a lack of high-quality evidence and, until this exists, we recommend continuing to consider new daily persistent headache a distinct disorder.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje